Expression of Urokinase-type Plasminogen Activator and its Receptor in Keloids

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 12, 2003, Pages 1334-1338

  Leake, Deirdre ^a   Doerr, Timothy D ^a   Scott, Glynis ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KELOID; PROTEIN LOCALIZATION;

CELL MOVEMENT; CICATRIX; CONFOUNDING FACTORS (EPIDEMIOLOGY); EXTRACELLULAR MATRIX; HUMANS; IMMUNOHISTOCHEMISTRY; KELOID; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR; WOUND HEALING;

EID: 0346220301     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.12.1334     Document Type: Article

References (32)

1. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today. 1998;4:19-24.
2. English RS, Shenefelt PD. Keloids and hypertrophic scars. Dermatol Surg. 1999; 25:631-638.
3. Sherris DA, Larrabee WF Jr, Murakami CS. Management of scar contractures, hypertrophic scars, and keloids. Otolaryngol Clin North Am. 1995;28:1057-1068.
4. Lim IJ, Phan TT, Song C, Tan WT, Longaker MT. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstr Surg. 2001;107:797-808.
5. Chin GS, Liu W, Steinbrech D, Hsu M, Levinson H, Longaker MT. Cellular signaling by tyrosine phosphorylation in keloid and normal human dermal fibroblasts. Plast Reconstr Surg. 2000;106:1532-1540.
6. Weidle UH, Wollisch E, Ronne E, et al. Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy. Ann Biol Clin (Paris). 1994;52:775-782.
7. Blasi F. The urokinase receptor: a cell surface, regulated chemokine. APMIS. 1999; 107:96-101.
8. Pollanen J, Stephens R, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res. 1991;57:273-328.
9. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 1985; 44:139-266.
10. Ito Y, Takeda T, Kobayashi T, et al. Plasminogen activation system is active even in thyroid tumors: an immunohistochemical study. Anticancer Res. 1996;16:81-90.
11. Pollanene J, Saksela O, Salonen EM, et al. Distinct localization of uroinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol. 1987;104:1085-1096.
12. Pollanene J, Hedman K, Nielsen LS, Dano K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contact sites. J Cell Biol. 1988;106:87-95.
13. Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison of urokinase levels. Cancer Res. 1993;53:3198-3206.
14. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate. 1999;39:123-129.
15. Morita Y, Hayashi Y, Wang Y, et al. Expression of urokinase-type plasminogen receptor in hepatocellular carcinoma. Hepatology. 1997;25:856-861.
16. Nozaki S, Endo Y, Kawashiri S, et al. Immunohistochemical localization of urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol. 1998;34:58-62.
17. Kennedy S, Duffy MJ, Duggan C, Barnes C, Rafferty R, Kramer MD. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Br J Cancer. 1998;77:1638-1641.
18. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-336.
19. Brunner N, Pyke C, Hansen CH, Romer J, Grondahl-Hansen J, Dano K. Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res. 1994;71:299-309.
20. Casslen B, Bossmar T, Lecander I, Astedt B. Plasminogen activators and plasminogen, activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer. 1994;30A:1302-1309.
21. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer. 1997;79:878-883.
22. Stahl A, Mueller BM. Binding of urokinase to its receptor promote migration and invasion of human melanoma cells in vitro. Cancer Res. 1994;54:3066-3071.
23. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-tupe plasminogen activator in human astrocytomas in vivo. Cancer Res. 1994;54:3656-3661.
24. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR. Clinial value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res. 1993;53:1788-1793.
25. Pedersen AN, Hoyer-Hansen G, Brunner N, et al. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantified by ELISA. J Immunol Methods. 1997;203:55-65.
26. Terris D. Dynamics of wound healing. In: Bailey BJ, ed. Head and Neck Surgery-Otolaryngology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: 175-188.
27. Bloch EF, Hall MG Jr, Denson MJ, Slay-Solomon V. General immune reactivity in keloid patients. Plast Reconstr Surg. 1984;73:448-451.
28. Xue H, McCauley RL, Zhang W. Elevated interleukin-06 expression in keloid fibroblasts. J Surg Res. 2000;89:74-77.
29. Ishihara H, Yoshimoto H, Fujioka M, et al. Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor. J Invest Dermatol. 2000;115:1065-1071.
30. Lou S, Benathan M, Raffoul W, Panizzon RG, Egloff DV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg. 2001;107:87-96.
31. Morita Y, Hayashi Y, Wang Y, et al. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology. 1997;25:856-861.
32. Levenson SM, Gever EF, Crowley LV, Oates JF, Berard CW, Rosen H. The healing of rat skin wounds. Ann Surg. 1965;161:293-308.